Lotus Eye Hospital And Institute (NSE: LOTUSEYE, BSE: 532998) is a Coimbatore, Tamil Nadu-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹222 Cr, it ranks #2,566 by market cap among the 6,197 Indian listed companies on FinBizNet, and #29 of 46 in Hospitals and Healthcare Centers. At ₹105.85 (as of 16 Nov 2026), the share price is 28.0% below its 52-week high of ₹147.00 and 8.5% above its 52-week low of ₹97.59. The share price is down 16.4% over one year and down 11.6% over three months.
| Current Price | ₹105.85 |
|---|---|
| Market Cap | ₹222 Cr |
| NSE Symbol | LOTUSEYE |
| BSE Code | 532998 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 2,562.5 |
| Return on Equity | 0.13% |
| Return on Assets | 0.07% |
| 52-Week Range | ₹97.59 – ₹147.00 |
| 1-Year Price Change | -16.4% |
| 3-Month Price Change | -11.6% |
| Beta (1Y) | 0.15 |
| Dividend Yield | 0.00% |
| Headquarters | Coimbatore, Tamil Nadu |
| Website | www.lotuseye.org |
| Revenue | ₹18 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 2.5% |
| EPS (Basic) | ₹0.21 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lotus Eye Hospital And Institute reported revenue of ₹18 Cr in Q2 FY27, up 35.9% from ₹13 Cr in Q2 FY26 and up 3.9% from ₹17 Cr in Q1 FY27. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (up 266.7%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹12 Cr (Q4 FY25) to ₹18 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹18 Cr | ₹0 Cr | 2.5% |
| Q1 FY27 | ₹17 Cr | ₹1 Cr | 3.6% |
| Q4 FY26 | ₹14 Cr | −₹0 Cr | −2.4% |
| Q3 FY26 | ₹14 Cr | −₹0 Cr | −1.9% |
| Q2 FY26 | ₹13 Cr | ₹0 Cr | 0.9% |
| Q1 FY26 | ₹14 Cr | ₹1 Cr | 4.0% |
| Q4 FY25 | ₹12 Cr | ₹0 Cr | 2.2% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 40.14% of Lotus Eye Hospital And Institute's shares as of Sept 2026, against 40.64% in Sept 2025 (−0.50 percentage points). Delivery averaged 83.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 198
1. Providing Health Care (Eye Care) Services-This segment engages in the provision of healthcare services in India. It provides services in the areas of cataract, retina, glaucoma, refractive surgery, cornea, orbit and oculoplasty, squint, uvea, neuro and paediatric ophthalmology, headache, and low vision aid.
1. Eye Care Related Sales and Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Lotus Eye Hospital And Institute | ₹222 Cr | 2,562.5 | 0.13% | ₹18 Cr | -16.4% |
Listed by market capitalisation. Ratios are shown for context only.
Lotus Eye Hospital And Institute is trading at ₹105.85, with a market capitalisation of ₹222 Cr.
Lotus Eye Hospital And Institute operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Lotus Eye Hospital And Institute has a P/E of 2,562.5 and a return on equity of 0.13%.
Lotus Eye Hospital And Institute is listed on the NSE under the symbol LOTUSEYE and on the BSE under the scrip code 532998.
Lotus Eye Hospital And Institute's share price is down 16.4% over one year and down 11.6% over three months. Its 52-week range is ₹97.59 to ₹147.00.
In Q2 FY27, Lotus Eye Hospital And Institute reported revenue of ₹18 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.21 (standalone, parsed from the company's exchange filing).
Lotus Eye Hospital And Institute reported revenue of ₹18 Cr in Q2 FY27, up 35.9% from ₹13 Cr in Q2 FY26 and up 3.9% from ₹17 Cr in Q1 FY27.
Promoters held 40.14% of Lotus Eye Hospital And Institute's shares as of Sept 2026, against 40.64% in Sept 2025 (−0.50 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.